Details for New Drug Application (NDA): 213994
✉ Email this page to a colleague
NDA 213994 describes EPHEDRINE SULFATE, which is a drug marketed by Amneal, Caplin, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Mankind Pharma, Ph Health, Renew Pharms, Sagent Pharms Inc, Sandoz, Xiromed, and Zydus Pharms, and is included in seventeen NDAs. It is available from nineteen suppliers. There are two patents protecting this drug. Additional details are available on the EPHEDRINE SULFATE profile page.
The generic ingredient in EPHEDRINE SULFATE is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.
The generic ingredient in EPHEDRINE SULFATE is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.
Summary for 213994
| Tradename: | EPHEDRINE SULFATE |
| Applicant: | Ph Health |
| Ingredient: | ephedrine sulfate |
| Patents: | 2 |
Pharmacology for NDA: 213994
| Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
| Physiological Effect | Increased Norepinephrine Activity |
Medical Subject Heading (MeSH) Categories for 213994
Suppliers and Packaging for NDA: 213994
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213994 | NDA | ENDO USA, Inc. | 42023-243 | 42023-243-01 | 10 mL in 1 VIAL, SINGLE-DOSE (42023-243-01) |
| EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213994 | NDA | ENDO USA, Inc. | 42023-243 | 42023-243-99 | 10 mL in 1 VIAL, SINGLE-DOSE (42023-243-99) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 50MG/10ML (5MG/ML) | ||||
| Approval Date: | Oct 16, 2020 | TE: | AP2 | RLD: | Yes | ||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jan 22, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 25MG/5ML (5MG/ML) | ||||
| Approval Date: | Apr 22, 2022 | TE: | AP2 | RLD: | Yes | ||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jan 22, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jan 22, 2040 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF CLINICALLY IMPORTANT HYPOTENSION OCCURRING IN THE SETTING OF ANESTHESIA | ||||||||
Complete Access Available with Subscription
